Breda, the Netherlands/Ghent, Belgium– arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET.
Voting results
The results of the votes will be posted shortly on the Company's websitewww.argen-x.com/shareholders-meeting.
Changes to the board of directors
As previously announced, Dr. H. van Barlingen and Dr. B. Montanari have resigned from the board of directors as non-executive directors with effect as per the date of the meeting, to be replaced by independent industry professionals in line with the Dutch Corporate Governance Code.
Mr. Donald (Don) deBethizy was appointed as non-executive director to the board. Don has 30 years of experience in research and development, financial, business, and operating management in the biotechnology and consumer products industry. Don is currently President of White City Consulting ApS in Denmark. He served as President and CEO of Santaris Pharma A/S, Denmark and USA until September 2014 when the Company was sold to Roche.
Adoption of 2014 financial statements
Furthermore, the Company's financial statements for the 2014 financial year were adopted by the shareholder meeting. The 2014 Annual report and Accounts are available to shareholders in the ‘Investor’ section of the Company's website atwww.argen-x.com. Paper copies are available upon request to the Company.
